Similarly in our study, ZNF703 was the only full-length gene within the SRO in two luminal B tumors that had a centromeric break point within ERLIN2. The previous studies 16–17 provided support for ZNF703 being a class II oncogene in luminal B breast tumors in keeping with a scheme that classifies amplified cancer genes according to importance in cancer development 34. This evidence concerns the gene ZNF703 and breast neoplasm.